Nohla Therapeutics has hired Sarah Noonberg to serve as its chief medical officer. She takes the place of Nohla founder Colleen Delaney, who is now the Seattle biotech’s chief scientific officer. Noonberg most recently worked at Prothena (NASDAQ: PRTA), where she was chief medical officer. Her experience also includes positions at BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation. Nohla’s lead therapeutic candidate, dilanubicel, was developed to temporarily restore bone marrow function in cord blood transplant patients, as well as those receiving high doses of chemotherapy. The experimental treatment is currently in Phase 2 studies.